Lifesaving liver disease medicines
Versantis develops a new generation of liver disease therapeutics and diagnostics.
We are committed to the translation of life-saving therapies for acute hepatic diseases, where the medical need is dramatically high.
A life-saving therapy
Versantis’ lead product candidate, VS-01, is being advanced into a Phase 2a clinical trial for the treatment of Acute-on-Chronic Liver Failure (ACLF). VS-01 was granted orphan drug designations from both FDA and EMA and has the potential to target the liver deficiencies associated with high unmet need and cost of care, such as acute hepatic encephalopathy (acute HE), ACLF, cirrhosis decompensation,or urea cycle disorders (UCDs). The versatile mechanism of action of VS-01 can simultaneously support multiple affected organ functions (liver, kidneys, brain), encourage liver regeneration, and save patients’ lives.
Versantis selected among the top 25 Scale-up companies in Switzerland!
Versantis extends its R&D team with Leo Hofmann as R&D Project Lead. Welcome on board!